These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 37705485)

  • 1. Alpha-2 macroglobulin activity in SARS-CoV-2 induced infection and in the post-COVID-19 period.
    Akbasheva OE; Mitrofanova DK; Spirina LV; Samoilova YG; Matveeva MV; Podchinenova DV; Oleynik OA
    Biomed Khim; 2023 Sep; 69(4):240-247. PubMed ID: 37705485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Proteolysis and deficiency of α1-proteinase inhibitor in SARS-CoV-2 infection].
    Akbasheva OE; Spirina LV; Dyakov DA; Masunova NV
    Biomed Khim; 2022 Jun; 68(3):157-176. PubMed ID: 35717581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantifying the effect of trypsin and elastase on in vitro SARS-CoV infections.
    Rodriguez T; Dobrovolny HM
    Virus Res; 2021 Jul; 299():198423. PubMed ID: 33845063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 Infection of Human Neurons Is TMPRSS2 Independent, Requires Endosomal Cell Entry, and Can Be Blocked by Inhibitors of Host Phosphoinositol-5 Kinase.
    Kettunen P; Lesnikova A; Räsänen N; Ojha R; Palmunen L; Laakso M; Lehtonen Š; Kuusisto J; Pietiläinen O; Saber SH; Joensuu M; Vapalahti OP; Koistinaho J; Rolova T; Balistreri G
    J Virol; 2023 Apr; 97(4):e0014423. PubMed ID: 37039676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myoclonus status revealing COVID 19 infection.
    Ben Mohamed D; Zouari R; Ketata J; Nabli F; Blel S; Ben Sassi S
    Seizure; 2023 Jan; 104():12-14. PubMed ID: 36446232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Shedding of SARS-CoV-2 Virus in COVID-19 Patients and Neutralizing Antibody Level].
    Ayhancı T; Toptan H; Özer YE; Uzar S; Enül H; Adıay C; Sarac F; Dheir H; Köroğlu M; Hasöksüz M; Altındiş M
    Mikrobiyol Bul; 2022 Jul; 56(3):416-431. PubMed ID: 35960235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A substrate for a cell free in vitro assay system to screen drugs targeting trypsin like protease-based cleavage of SARS-CoV-2 spike glycoprotein and viral entry.
    Begum F; Srivastava AK; Tripathi PP; Ray U
    J Med Virol; 2023 May; 95(5):e28796. PubMed ID: 37218551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interaction of alpha2-macroglobulin with proteinases. Binding and inhibition of mammalian collagenases and other metal proteinases.
    Werb Z; Burleigh MC; Barrett AJ; Starkey PM
    Biochem J; 1974 May; 139(2):359-68. PubMed ID: 4374931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of SARS-CoV-2 by trypsin-like proteases in the clinical specimens of patients with COVID-19.
    Yamazaki E; Yazawa S; Shimada T; Tamura K; Saga Y; Itamochi M; Inasaki N; Hasegawa S; Morinaga Y; Oishi K; Tani H
    Sci Rep; 2023 Jul; 13(1):11632. PubMed ID: 37468582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteinase binding and inhibition by the monomeric alpha-macroglobulin rat alpha 1-inhibitor-3.
    Enghild JJ; Salvesen G; Thøgersen IB; Pizzo SV
    J Biol Chem; 1989 Jul; 264(19):11428-35. PubMed ID: 2472396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The impact of BMI on the course of the acute SARS-COV-2 infection and the risks that emerge during the first year after the hospital discharge. Subanalysis evidence of the AKTIV and AKTIV 2 registries].
    Arutyunov AG; Tarlovskaya EI; Galstyan GR; Batluk TI; Bashkinov RA; Arutyunov GG; Belenkov YN; Konradi AO; Lopatin YM; Rebrov AP; Tereshchenko SN; Chesnikova AI; Hayrapetyan HG; Babin AP; Bakulin IG; Bakulina NV; Balykova LA; Blagonravova AS; Boldina MV; Butomo MI; Vaisberg AR; Galyavich AS; Gomonova VV; Grigoryeva NY; Gubareva IV; Demko IV; Evzerikhina AV; Zharkov AV; Zateishchikova AA; Kamilova UK; Kim ZF; Kuznetsova TY; Kulikov AN; Lareva NAV; Makarova EV; Malchikova SV; Nedogoda SV; Petrova MM; Pochinka IG; Protasov KV; Protsenko DN; Ruzanov DY; Saiganov SA; Sarybaev AS; Selezneva NM; Sugraliev AB; Fomin IV; Khlynova OV; Chizhova OY; Shaposhnik II; Schukarev DA; Abdrakhmanova AK; Avetisyan SA; Avoyan HG; Azaryan KK; Aimakhanova GT; Ayypova DA; Akunov AC; Alieva MK; Almukhambedova AR; Aparkina AV; Aruslanova OR; Ashina EY; Badina ONY; Barysheva OY; Batchaeva AS; Bitieva AM; Bikhteev IU; Borodulina NA; Bragin MV; Brazhnik VA; Budu AM; Bykova GA; Vagapova KR; Varlamova DD; Vezikova NN; Verbitskaya EA; Vilkova OE; Vinnikova EA; Vustina VV; Galova EA; Genkel VV; Giller DB; Gorshenina EI; Grigoryeva EV; Gubareva EY; Dabylova GM; Demchenko AI; Dolgikh OY; Duishobaev MY; Evdokimov DS; Egorova KE; Ermilova AN; Zheldybaeva AE; Zarechnova NV; Zimina YD; Ivanova SY; Ivanchenko EY; Ilina MV; Kazakovtseva MV; Kazymova EV; Kalinina YS; Kamardina NA; Karachenova AM; Karetnikov IA; Karoli NA; Karsiev MK; Kaskaeva DS; Kasymova KF; Kerimbekova ZB; Kim ES; Kiseleva NV; Klimenko DA; Klimova AV; Kovalishena OV; Kozlov SV; Kolmakova EV; Kolchinskaya TP; Kolyadich MI; Kondryakova OV; Konoval MP; Konstantinov DY; Konstantinova EA; Kordyukova VA; Koroleva EV; Kraposhina AY; Kryukova TV; Kuznetsova AS; Kuzmina TY; Kuzmichev KV; Kulchoroeva CK; Kuprina TV; Kuranova IAM; Kurenkova LVV; Kurchugina NY; Kushubakova NA; Levankova VI; Ledyaeva AA; Lisun TV; Lisyanskaya VE; Lyubavina NA; Magdeeva NA; Mazalov KV; Mayseenko VI; Makarova AS; Maripov AM; Markov NV; Marusina AA; Melnikov ES; Metlinskaya AI; Moiseenko NB; Muradova FN; Muradyan RG; Musaelyan SN; Nekaeva ES; Nikitina NM; Nifontov SE; Obolentseva EY; Obukhova AA; Ogurlieva BB; Odegova AA; Omarova YV; Omurzakova NA; Ospanova SO; Pavlova VA; Pakhomova EVP; Petrov LD; Plastinina SS; Platonov DA; Pogrebetskaya VAA; Polyakov DV; Polyakov DS; Ponomarenko EEV; Popova LL; Potanin AA; Prokofieva NA; Rabik YD; Rakov NA; Rakhimov AN; Rozanova NA; Samus IV; Serikbolkyzy S; Sidorkina YA; Simonov AA; Skachkova VV; Skvortsova RD; Skuridin DS; Solovieva DV; Solovieva IA; Sukhomlinova IM; Sushilova AG; Tagaeva DR; Titoykina YV; Tikhonova EP; Tokmin DS; Tolmacheva AA; Torgunakova MS; Trenogina KV; Trostyanetskaya NAA; Trofimov DA; Trubnikova MA; Tulichev AA; Tursunova AT; Ulanova ND; Fatenkov OV; Fedorishina OV; Fil TS; Fomina IY; Fominova IS; Frolova IA; Tsvinger SM; Tsoma VV; Cholponbaeva MB; Chudinovskikh TSI; Shavrin IV; Shevchenko OA; Shikhaliev DR; Shishkina EA; Shishkov KY; Shcherbakov SY; Shcherbakova GV; Yausheva EA
    Probl Endokrinol (Mosk); 2023 Jan; 68(6):89-109. PubMed ID: 36689715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC.
    Anand P; Puranik A; Aravamudan M; Venkatakrishnan AJ; Soundararajan V
    Elife; 2020 May; 9():. PubMed ID: 32452762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteinase inhibitory spectrum of mouse murinoglobulin and alpha-macroglobulin.
    Abe K; Yamamoto K; Sinohara H
    J Biochem; 1989 Oct; 106(4):564-8. PubMed ID: 2481676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection.
    Ryan FJ; Hope CM; Masavuli MG; Lynn MA; Mekonnen ZA; Yeow AEL; Garcia-Valtanen P; Al-Delfi Z; Gummow J; Ferguson C; O'Connor S; Reddi BAJ; Hissaria P; Shaw D; Kok-Lim C; Gleadle JM; Beard MR; Barry SC; Grubor-Bauk B; Lynn DJ
    BMC Med; 2022 Jan; 20(1):26. PubMed ID: 35027067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions of the complex between human urinary trypsin inhibitor and human leukocyte elastase with alpha 1-proteinase inhibitor and alpha 2-macroglobulin.
    Jönsson BM; Ohlsson K
    Hoppe Seylers Z Physiol Chem; 1984 Dec; 365(12):1403-8. PubMed ID: 6084636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.